SEC Form 4 · accession 0001209191-16-087741
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Dec 30, 2015
Accepted (ET)
Jan 4, 2016 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 30, 2015 | M | 10,400 | $35.64 | A | 275,684 | D | |
| Common StockF2,F3 | Dec 30, 2015 | S | 7,300 | $126.98 | D | 268,384 | D | |
| Common StockF2,F4 | Dec 30, 2015 | S | 3,100 | $127.55 | D | 265,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401k | |
| Common Stock | holding | — | — | — | 122,700 | I | Common Stock Held In Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $35.64 | Dec 30, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 42,400 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $126.98 (range $126.38 to $127.37).
- F4Open market sales reported on this line occurred at a weighted average price of $127.55 (range $127.38 to $127.83).
- F5Fully vested.